In direct compression tablet manufacture, the N-nitroiminoimidazolidine API is introduced as a pharmaceutical-grade solid with controlled particle size and residual solvent profile under ICH Q3C(R8). A representative development formulation contains 4.0% w/w API, 94.5% w/w microcrystalline cellulose, 1.0% w/w croscarmellose sodium, and 0.5% w/w magnesium stearate. The API is first passed through a 0.5 mm woven stainless-steel sieve to break soft agglomerates, then blended in an IBC bin blender at 12–18 rpm for 15 minutes before lubrication for 3 minutes. Compression is carried out on a 16/24-station rotary tablet press with 8 kN precompression and 15 kN main compression force, producing a 250.0 mg ± 5.0% tablet core with hardness of 80–120 N. Finished-product control is anchored to USP <905> Uniformity of Dosage Units, Ph. Eur. 2.9.40, 21 CFR 211.110 in-process control, and USP <711> dissolution using Apparatus II at 50 rpm in 900 mL of the validated medium. Friability is tested under Ph. Eur. 2.9.7 with a limit of not more than 1.0% after 100 revolutions. The primary process failure observed on rotary presses is content variation caused by blend segregation at the start, middle, and end of the run; this is controlled by precompression force, storage of the blend in sealed stainless-steel totes, and HPLC assay with acceptable blend uniformity set at 90.0–110.0% label claim and RSD not more than 5.0%. The terminal product is an immediate-release tablet core intended for film coating or push-through blister packaging. Operational boundaries include moisture uptake above 60% RH and ejection friction from insufficient lubricant, which are addressed by humidity-controlled storage and by confirming dissolution impact before increasing magnesium stearate content.

Because the API can segregate in dry blends, direct compression batches are routinely sampled at the initial, middle, and final compression stages. This in-process sampling is performed under 21 CFR 211.110 and is designed to detect batch-to-batch variance caused by differences in API particle-size distribution or microcrystalline cellulose bulk density. Tablet weight variation is maintained by press turret speed, feeder paddle speed, and die fill depth, with the target tablet weight and hardness ranges defined before process validation.

What Filling Parameters Govern Low-Dose Capsule Uniformity?

Low-dose capsule filling with the N-nitroiminoimidazolidine API requires ordered mixing to prevent particle adhesion and agglomeration before encapsulation. In a representative development formula, the API is first pre-dispersed at 1.0% w/w onto lactose monohydrate; the final hard gelatin or HPMC capsule blend is prepared at 1.0% w/w API, 98.0% w/w lactose monohydrate, 0.5% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The blend is encapsulated into size 3 shells at a fill weight of 150.0 mg ± 5.0% using a dosator-type or tamping-pin capsule filler. Dosator settings are adjusted to achieve plug density between 0.65 g/cm³ and 0.80 g/cm³, while tamping-pin machines are set to 2–4 tamps at 5–8 mm compression depth. Weight uniformity is controlled under Ph. Eur. 2.9.5 Uniformity of Mass of Single-Dose Preparations and USP <905>; content uniformity on filled capsules uses an acceptance value of not more than 15.0, and dissolution is evaluated using USP <711> Apparatus II or I depending on capsule floating behavior. The terminal products are hard gelatin capsules and HPMC capsules for oral administration. The most common process failure is static adhesion of the API to the internal capsule wall under low-humidity conditions below 30% RH, which is mitigated by maintaining the encapsulation suite at 40–50% RH and 22–25°C. Fill weight drift is also observed on dosator machines as powder bed height decreases; this is controlled by maintaining bed height above the dosator intake port and by periodic weight checks every 15 minutes.

High-shear wet granulation of the N-nitroiminoimidazolidine API is used when direct compression cannot deliver adequate flow or content uniformity for low-dose sachet granules. A representative dry granulate contains 8.0% w/w API, 88.0% w/w lactose monohydrate, 3.0% w/w pregelatinized starch, and 1.0% w/w povidone K30 as binder. The dry blend is granulated in a high-shear mixer at impeller 300 rpm and chopper 1500 rpm, with purified water added at 15.0% w/w of dry mass; wet mass is sieved through a 1.0 mm screen, dried in a fluid bed dryer at inlet temperature 60–65°C to a final loss on drying of 1.5–2.5%, and filled into sachets on a vertical form-fill-seal machine with a fill weight of 1.00 g ± 3.0%. Particle size distribution is controlled under Ph. Eur. 2.9.12; dissolution of the finished granules is performed according to USP <711>; and stability is conducted under ICH Q1A(R2) in climatic zones I–IV. The terminal product is a unit-dose granulate in stick-packs or sachets for oral administration after dispersion in water. The critical processing limit is the moisture sensitivity of the wet mass, which requires drying endpoint control and immediate sealing of sachets below 25% RH. If the nitroiminoimidazolidine structure is vulnerable to alkaline hydrolysis, the binder solution should be aqueous or hydroalcoholic rather than alkaline, and forced degradation data should be generated before selecting the granulation medium.

Batch-to-batch variance in high-shear granulation is commonly observed when lactose monohydrate has variable moisture content. The addition of purified water is therefore adjusted by near-infrared or mass-loss dosing to maintain a consistent wet-mass endpoint, and the chopper speed is held constant to avoid overwetting. Drying curves are recorded with inlet and outlet air temperature monitors, and the final LOD is confirmed before sachet filling to prevent powder blocking or seal contamination.

When the API Is Processed as a Ready-to-Use Injectable Solution

Ready-to-use injectable solutions of the N-nitroiminoimidazolidine API require pre-formulation solubility and forced degradation data before terminal sterilization or aseptic filtration is selected. A development formulation at 1.0 mg/mL API corresponds to 0.1% w/v active substance in a sterile vehicle of 0.9% w/v sodium chloride injection, adjusted with 0.1 N hydrochloric acid or sodium hydroxide to a target pH of 5.5 ± 0.5; the solution is sparged with nitrogen to reduce oxidative degradation. Manufacturing is performed in a Grade C background with Grade A filling, using a 0.22 µm two-stage polyethersulfone or PVDF sterilizing-grade filter. If thermal stability permits, filled vials are terminally sterilized at 121°C for 15 minutes, but published data for this specific nitroiminoimidazolidine configuration is limited, so aseptic filtration with post-fill filter integrity testing is the default control until forced degradation data confirm autoclave tolerance. The product is tested under USP <1> Injections, USP <788> Particulate Matter in Injections for sub-visible particles, USP <790> Visible Particulates, Ph. Eur. 2.9.19 Particulate Contamination, and 21 CFR 211.94(b) container-closure protection; endotoxin limits follow USP <85> or Ph. Eur. 2.6.14 for the specified route. Terminal products are single-dose aqueous injections filled into amber borosilicate glass vials with rubber stoppers under nitrogen headspace. The main incompatibility is oxidation of the nitroimino group, which is controlled by low headspace oxygen and light-protective packaging. Elastomeric closures containing mercapto or amine-based curing systems should also be screened because the nitroimino moiety may be reactive toward nucleophilic extractables.

Sub-visible particulate limits for small-volume injections are controlled under USP <788> Method 1: not more than 6,000 particles per container at 10 µm or larger and not more than 600 particles per container at 25 µm or larger. Osmolality is measured by freezing point depression under USP <785> and adjusted with sodium chloride to 280–320 mOsm/kg. The sterile filtration process is monitored by differential pressure across the 0.22 µm membrane, and the fill line is operated at a maximum of 24 hours between filter replacement and integrity testing to avoid membrane plugging from undissolved API fractions.

For freeze-dried injection powder manufacture, the N-nitroiminoimidazolidine API is compounded into a pre-lyophilization solution at 2.0% w/v API and 4.0% w/v mannitol, filled at 5.0 mL per 10 mL glass tubing vial, and dried in a shelf lyophilizer with a shelf ramp from -40°C to -20°C primary drying at chamber pressure 100 mTorr, followed by secondary drying at 25°C until the cake reaches a residual moisture content of not more than 3.0%. Residual moisture is determined by coulometric Karl Fischer titration under USP <921> Method Ic; container closure integrity is assessed per USP <1207>; sterility is confirmed under USP <71>; and sub-visible particulates are tested after reconstitution per USP <788> and Ph. Eur. 2.9.19. The critical process parameter is the collapse temperature of the frozen solution; because published thermal analysis data for this specific API is limited, differential scanning calorimetry and freeze-dry microscopy are performed before scale-up to set the primary drying shelf temperature at least 5°C below the collapse onset. The finished lyophilized cake is reconstituted with 0.9% w/v sodium chloride injection at the point of use. The terminal product is a single-dose lyophilized cake for reconstitution into injectable solution, and the main operational boundary is the need to maintain chamber cleanliness and to perform filter integrity testing after the filtration step.

The lyophilization cycle is designed so that the product temperature during primary drying remains below the collapse onset, and the chamber pressure is controlled by a capacitance manometer rather than a Pirani gauge to improve reproducibility. Vial seating uniformity on the lyophilizer shelf is checked before loading because uneven heat transfer can raise residual moisture and produce collapsed cakes in the center of the batch. After stopper closure under partial vacuum or nitrogen, container-closure integrity is verified using dye ingress or vacuum decay following USP <1207>.

Compression Force, Disintegration Time, and Moisture Uptake in Oral Disintegrating Tablet Manufacture

Oral disintegrating tablets containing the N-nitroiminoimidazolidine API are produced by direct compression with highly water-soluble excipients to achieve rapid disintegration. A representative core formula contains 5.0% w/w API, 90.0% w/w mannitol, 4.0% w/w crospovidone, and 1.0% w/w magnesium stearate, compressed to a core weight of 100.0 mg ± 5.0% and hardness of 40–60 N. Compression is performed on a 16/24-station rotary tablet press with precompression of 4 kN and main compression of 8–12 kN; the low compression force preserves tablet porosity and enables disintegration in 30 seconds or less in 900 mL water at 37°C per USP <701> and Ph. Eur. 2.9.1. Content uniformity is tested per USP <905> and Ph. Eur. 2.9.40; moisture uptake is controlled by packaging the tablets in polyvinylidene chloride-coated aluminum blisters with desiccant; storage below 25°C and 40% RH is assessed under ICH Q1A(R2). The terminal product is a direct-compressed oral disintegrating tablet intended for oral administration without water. The main process limitation is the tendency of mannitol-based compacts to cap under excessive main compression, so the upper compression force is deliberately kept below 12 kN and the magnesium stearate level is not increased without evaluating disintegration time and tensile strength.

In production, the disintegration time is measured at the start, middle, and end of the compression run because prolonged press operation can heat the punches and reduce tablet porosity. Tablet punches are cleaned and inspected for sticking or picking, and the hopper relative humidity is maintained below 30% RH to prevent mannitol surface wetting. If rapid disintegration is not achieved, crospovidone may be increased in small increments while holding compression force constant; however, the addition ratio of API is fixed by the unit dose and cannot be adjusted independently of the approved product specification.